The Effect of Varenicline (Chantix) and Bupropion (Zyban) on Smoking Lapse Behavior

• Status: Completed
• Trial end date: 2016-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to examine how smoking cessation medications (varenicline, bupropion) affect the ability to resist smoking and also subsequent ad-lib smoking in non-treatment seeking daily smokers.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yale University
• Collaborator: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
• Treatments: Bupropion; Varenicline

Criteria

Inclusion Criteria:

• ages 18-55

• able to read and write in English

• Smokers

Exclusion Criteria:

• any significant current medical or psychiatric conditions that would contraindicate smoking

• current Diagnostic and Statistical Manual IV abuse or dependence of other substances, other than nicotine dependence or alcohol abuse

• positive test result at intake appointments on urine drug screens conducted for opiates, cocaine, or benzodiazepines

• women who are pregnant or nursing

• suicidal, homicidal, or evidence of current severe mental illness

• participants prescribed any psychotropic drug in the 30 days prior to study enrollment

• blood donation within the past 6 weeks

• individuals seeking treatment for smoking cessation or have attempted to quit smoking within the past 3 months

• specific exclusions for bupropion administration not already specified, including:

have taken monoamine inhibitors in the past 6 weeks; history of anorexia or bulimia; previous hypersensitivity to bupropion; history of alcohol or drug dependence in the past year; history of seizure disorder of any etiology

• known allergy to varenicline or taking H2blockers

• participation within the past 8 weeks in other studies that involve additive blood sampling and/or interventional measures that would be considered excessive in combination with the current study